Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of β-chemokines

AIDS Research and Human Retroviruses

Volumn 26, Issue 10, 2010, Pages 1147-1154

  Tanaka, Reiko ^a   Takahashi, Yoshiaki ^b   Kodama, Akira ^a   Saito, Mineki ^a   Ansari, Aftab A ^b   Tanaka, Yuetsu ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; IMMOBILIZED ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; NEUTRALIZING ANTIBODY; OX40 LIGAND; RANTES;

ARTICLE; BLOOD DONOR; CD4+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYNCYTIUM;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINE CCL5; CHEMOKINES, CC; HIV INFECTIONS; HIV-1; HUMANS; OX40 LIGAND; RECEPTORS, CCR5; RECEPTORS, OX40;

EID: 77958164947     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0043     Document Type: Article

References (45)

1. Croft M, So T, Duan W, and Soroosh P: The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009;229(1):173-191.
2. Redmond WL, Ruby CE, and Weinberg AD: The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 2009;29(3):187-201.
3. Paterson DJ, Jefferies WA, Green JR, et al.: Antigens of activated rat T lymphocytes including a molecule of 50, 000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987;24(12):1281-1290.
4. Strober S, Cheng L, Zeng D, et al.: Double negative (CD4-CD8-alpha beta+) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev 1996;149:217-230.
5. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, and Croft M: The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000;165(6):3043-3050.
6. Mallett S, Fossum S, and Barclay AN: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor. EMBO J 1990;9(4):1063-1068.
7. Fujita T, Ukyo N, Hori T, and Uchiyama T: Functional characterization of OX40 expressed on human CD8+T cells. Immunol Lett 2006;106(1):27-33.
8. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C, and Simon HU: Functional expression of CD134 by neutrophils. Eur J Immunol 2004;34(8):2268-2275.
9. Zhou D: OX40 signaling directly triggers the antitumor effects of NKT cells. J Clin Invest 2007;117(11):3169-3172.
10. Tanaka Y, Inoi T, Tozawa H, Yamamoto N, and Hinuma Y: A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int J Cancer 1985;36(5):549-555.
11. Miura S, Ohtani K, Numata N, et al.: Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 1991;11(3):1313-1325.
12. Baum PR, Gayle RB 3rd, Ramsdell F, et al.: Molecular characterization of murine and human OX40/OX40 ligand systems: Identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 1994;13(17):3992-4001.
13. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, and Delespesse G: Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997;159(8):3838-3848.
14. Stuber E, Neurath M, Calderhead D, Fell HP, and Strober W: Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995;2(5):507-521.
15. Imura A, Hori T, Imada K, et al.: The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996;183(5):2185-2195.
16. Takasawa N, Ishii N, Higashimura N, et al.: Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. Jpn J Cancer Res 2001;92(4):377-382.
17. Kondo K, Okuma K, Tanaka R, et al.: Requirements for the functional expression of OX40 ligand on human activated CD4+and CD8+T cells. Hum Immunol 2007;68(7):563-571.
18. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, and Lanier LL: Cross-talk between activated human NK cells and CD4+T cells via OX40-OX40 ligand interactions. J Immunol 2004;173(6):3716-3724.
19. Kashiwakura J, Yokoi H, Saito H, and Okayama Y: T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: Comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 2004;173(8):5247-5257.
20. Ohshima Y, Yang LP, Uchiyama T, et al.: OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4 (+) T cells into high IL-4-producing effectors. Blood 1998;92(9):3338-3345.
21. Gramaglia I, Weinberg AD, Lemon M, and Croft M: Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161(12):6510-6517.
22. Ito T, Wang YH, Duramad O, et al.: TSLP-activated dendritic cells induce an inflammatory T helper type 2cell response through OX40 ligand. J Exp Med 2005;202(9):1213-1223.
23. Muller N, Wyzgol A, Munkel S, Pfizenmaier K, and Wajant H: Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J 2008;275(9):2296-2304.
24. Rogers PR, Song J, Gramaglia I, Killeen N, and Croft M: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001;15(3):445-455.
25. Takahashi Y, Tanaka R, Yamamoto N, and Tanaka Y: Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production. AIDS Res Hum Retroviruses 2008;24(3):423-435.
26. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
27. Grossman Z, Meier-Schellersheim M, Paul WE, and Picker LJ: Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 2006;12(3):289-295.
28. Takahashi Y, Tanaka Y, Yamashita A, Koyanagi Y, Nakamura M, and Yamamoto N: OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 2001;75(15):6748-6757.
29. Tozawa H, Andoh S, Takayama Y, et al.: Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I). Int J Cancer 1988;41(2):231-238.
30. Tanaka Y, Inoi T, Tozawa H, Sugamura K, and Hinuma Y: New monoclonal antibodies that define multiple epitopes and a human-specific marker on the interleukin 2 receptor molecules of primates. Microbiol Immunol 1986;30(4):373-388.
31. Tanaka Y, Yoshida A, Tozawa H, Shida H, Nyunoya H, and Shimotohno K: Production of a recombinant human T-cell leukemia virus type-I trans-activator (tax1) antigen and its utilization for generation of monoclonal antibodies against various epitopes on the tax1 antigen. Int J Cancer 1991;48(4):623-630.
32. Kondo K, Okuma K, Tanaka R, Matsuzaki G, Ansari AA, and Tanaka Y: Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions. Hum Immunol 2008;69(9):533-542.
33. Inudoh M, Kato N, and Tanaka Y: New monoclonal antibodies against a recombinant second envelope protein of hepatitis C virus. Microbiol Immunol 1998;42(12):875-877.
34. Yoshida A, Tanaka R, Murakami T, et al.: Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: Possible involvement of a novel factor of human CD4 (+) T-cell origin. J Virol 2003;77(16):8719-8728.
35. Tanaka R, Yoshida A, Murakami T, et al.: Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection. J Virol 2001;75(23):11534-11543.
36. Gaertner H, Lebeau O, Borlat I, et al.: Highly potent HIV inhibition: Engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4. Protein Eng Des Sel 2008;21(2):65-72.
37. Gulick RM, Lalezari J, Goodrich J, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359(14):1429-1441.
38. Jin H, Kagiampakis I, Li P, and Liwang PJ: Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES. Proteins 2010;78(2):295-308.
39. Yost R, Pasquale TR, and Sahloff EG.: Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 2009;66(8):715-726.
40. Liu J, Ngai N, Stone GW, Yue FY, and Ostrowski MA: The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009;27(37):5077-5084.
41. Dannull J, Nair S, Su Z, et al.: Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005;105(8):3206-3213.
42. Levine BL, Mosca JD, Riley JL, et al.: Antiviral effect and ex vivo CD4 + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272(5270):1939-1943.
43. Carroll RG, Riley JL, Levine BL, et al.: Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4 + T cells. Science 1997;276(5310):273-276.
44. Walker LS, Gulbranson-Judge A, Flynn S, et al.: Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med 1999;190(8):1115-1122.
45. Yu Q, Yue FY, Gu XX, Schwartz H, Kovacs CM, and Ostrowski MA: OX40 ligation of CD4+T cells enhances virusspecific CD8+T cell memory responses independently of IL-2 and CD4+T regulatory cell inhibition. J Immunol 2006;176(4):2486-2495.